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University	of	Calgary		
IGEM	Team	University	 of	 Calgary	 iGEM	team	 is	 composed	 of	 15	undergraduate	 students	 from	the	 faculties	 of	 science,	medicine,	 and	 engineering.	Each	year	they	tackle	solutions	to	 real-world	 problems	 using	synthetic	biology.	They	present	their	 work	 annually	 on	 the	global	 stage	 amongst	 250	teams	 at	 the	 International	Genetically	 Engineered	Machines	(iGEM)	competition.		
Abstract	The	 advancing	 industry	 of	 biotherapeutics	 is	 providing	 the	 public	 with	 new	 promising	 and	innovative	drugs	which	may	pose	risks	 if	 their	production,	distribution,	and	marketing	are	not	directly	governed	 by	 legislation.	 Apart	 from	 international	 agreements,	 such	 as	 the	 Cartagena	 Protocol	 that	governs	 the	migration	 of	 biotherapeutics	 between	 countries,	 there	 are	 no	 specific	 and	 direct	 laws	 or	regulations	governing	manipulated	cell-based	therapeutics	in	Canada.	The	introduction	of	these	laws	and	regulations	in	Canada	will	allow	for	the	safe	research	and	use	of	biotherapeutics	in	a	proactive	manner.				
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Introduction	The	emerging	biotechnology	sector	in	the	global	economy	combined	with	the	vast	amount	of	 research	 efforts	 into	 engineered	 cell-based	therapeutics	 alludes	 to	 the	 imminent	 creation	and	 marketization	 of	 engineered	 cell-therapy	drugs	 (hereby	 referred	 to	 as	 biotherapeutics)	[1].	 Effective	 planning	 of	 regulations	 and	economics	 will	 be	 necessary	 to	 better	 prepare	for	the	introduction	of	these	biotherapeutics	into	the	market.	Specific	regulations	can	both	serve	to	encourage	 expansion	 in	 this	 novel	 field,	 deter	misuse	of	this	technology,	and	prevent	potential	incidents	 that	 elicit	 risks	 from	 the	 use	 of	 this	group	of	drugs.	In	 the	 research	 community,	biotherapeutics	 have	 been	 appraised	 as	 the	emerging	 “third	 pillar”	 of	 pharmaceuticals	 after	synthetic	 chemicals	 and	 biologics	 [1].	 Biologics	are	 large	 molecules	 products	 that	 are	manufactured	 from	 living	 systems	 (live	 cells),	whereas	biotherapeutics	involve	the	use	of	these	live	cells	directly	[1].	The	use	of	live	cells	on	site	of	 the	human	body	offers	detection,	production,	and	 administration	 of	 therapeutics	 in	 a	responsive	 manner	 [1].	 This	 offers	 completely	novel	solutions	to	drug	administration	with	a	lot	of	 therapeutic	 potential.	 For	 instance,	 the	treatment	 of	 type	 1	 diabetes	 can	 be	revolutionized	 by	 planting	 engineered	 cells	 in	the	 body	 which	 can	 secrete	 insulin	 specifically	after	 detection	 of	 high	 blood	 glucose	 levels	 [1].	This	 would	 eliminate	 the	 need	 for	 attaching	extraneous	 electronic	 devices	 to	 the	 bodies	 of	diabetics.	 Other	 applications	 of	 this	 novel	technology	 include	 the	 use	 of	 engineered	bacterial	 cells	 to	 treat	 disorders	 of	 the	 human	microbiome	 (such	 as	 Clostridum	 difficile	infections),	 B	 lymphocytes	 to	 combat	 Epstein-Barr	 viral	 cancers,	 or	 providing	 regulated	production	 of	 lactase	 for	 individuals	 who	 are	lactose	intolerant	[1].	Previous	 literature	 reviews	 have	extensively	 covered	 the	 therapeutic	 potential	 of	biotherapeutics.[2][3]	 In	 the	 scientific	 field,	there	 is	 a	 surge	 of	 promising	 therapeutics	 that	emerged	 from	 cells	 modified	 using	 genetic	
engineering	 technologies.[4,5]	 Many	 of	 these	technologies	 are	 expected	 to	 enter	 clinical	 trial	stages	in	the	upcoming	years.	North	America	has	experienced	 tremendous	 growth	 in	 the	biotechnology	sector	in	the	last	5	years,	with	the	number	 of	 biotechnology	 companies	 increasing	by	 400%	 since	 2011	 [6].	 The	 biotechnology	sector	 currently	 totals	 $108.8	 billion	 annual	revenue	 [7].	 Furthermore,	 68.4%	 of	biotechnology	 companies	 focus	 mainly	 on	human	health	technologies,	which	is	evidence	for	the	 increasing	 availability	 and	 prevalence	 of	biotherapeutics	 [7].	 Thus,	 an	 appropriate	policy	framework	would	need	to	be	installed	to	ensure	these	 technologies	 are	 properly	 regulated	 and	contained.	 Policy	 frameworks	will	 also	 serve	 to	streamline	 the	 process	 of	 bringing	biotherapeutics	to	the	market.	The	 current	 Health	 Canada	 regulatory	frameworks	 (and	 international	 standards)	 are	shaped	 to	 address	 potential	 incidences	 with	chemically	 synthesized	 drugs,	 some	 biologic	products,	 and	 some	 stem	 cell	 therapy	applications	 [8,9].	 These	 Health	 Canada	regulations	 give	 some	 mention	 to	 synthetic	biology/genetically	 engineered	 products,	 but	these	 are	 descriptive	 at	 best	 [8,9].	 Prior	experiences	 pertaining	 to	 the	 introduction	 of	biologics	 has	 elucidated	 the	 importance	 of	parallel	 development	 of	 technological	discoveries	 and	 policy	 to	 avoid	 accidents	 [10].	Early	 planning	 for	 preventative	 purposes	 is	particularly	important	for	biotherapeutics	due	to	the	 rapid	 and	 far-reaching	 consequences	 that	could	occur	if	they	are	misused	[11].	The	 fragmentation	 of	 applicable	regulatory	 policies	 in	 separate	 guidance	documents,	 the	 dispersion	 of	 responsibilities	across	 ministries	 and	 agencies,	 and	 a	 limited	infrastructure	 appropriate	 for	 manufacture	 of	this	 novel	 technology	 could	 pose	 potential	challenges	 in	 its	 implementation.	Biotherapeutics	are	governed	by	many	separate	guidance	 documents	 under	 the	 current	framework,	 particularly	 through	 a	 combination	of	 cell-based	 therapeutics	 and	 gene	 therapy	documents	 [9].	 This	 separation	 leaves	 many	
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regulatory	gaps	where	 the	 interactions	between	separate	genes,	as	well	as	between	genes	and	cell	types	are	not	considered.	This	absence	of	specific	guidelines	 also	deters	 individuals	 from	entering	the	 field	 of	 biotherapeutics	 as	 a	 whole,	 which	impedes	its	growth.	This	 policy	 brief	 presents	 strategies	 that	can	 build	 an	 effective	 policy	 framework	 for	biotherapeutics	 and	 develop	 a	 comprehensive	knowledge	base	to	guide,	accelerate	and	improve	action.		
Strategies	for	Action	The	 introduction	 of	 specific	 regulations	pertaining	 to	 the	 development,	 manufacturing,	and	 ongoing	 surveillance	 of	 biotherapeutics	 is	pertinent	to	facilitate	the	safe	and	effective	use	of	this	drug	 technology.	For	such	regulations	 to	be	practical,	they	must:	
• build	off	of	existing	framework;	
• involve	the	coordinated	efforts	of	relevant	ministries,	 academic	 institutions,	companies,	and	other	relevant	partners;	
• require	 the	 financial	 and	 technical	support	 of	 governmental	 institutions,	and;	
• acquire	 political	 confirmation	 and	support	of	international	institutions.	The	 strategies	 outlined	 below	 should	 be	seen	 as	 complementary	 to	 one	 another,	 but	should	 be	 implemented	 concurrently	 for	maximum	impact.	
	
Existing	Policy	Currently,	 Health	 Canada	 has	 separate	categories	 of	 regulation	 for	 gene-engineering	products,	 including	 genetically	 modified	 foods	and	 drug	 products[12],	 and	 cell-based	therapeutic	 products,	 which	 includes	 guidance	on	 cell,	 tissue,	 and	 organ	 transplantation.[13]	Under	 the	 select	 agent	 compliance	 program	 of	Canada,	risk	classification	of	each	cell	type/gene	type	 is	 conducted	based	on	origin	and	 intended	use.[14]	 With	 risk	 considerations	 in	 mind,	 the	therapeutic	 is	 then	 given	 an	overall	 risk-benefit	score	 to	determine	approval.	The	assessment	of	a	 genetically	 engineered	 cell-product	 would	
warrant	first	a	risk	assessment	of	the	cell	type,	as	well	as	an	assessment	of	the	gene	origin	separate	from	one	another	under	the	current	policies.[11]	Although	 this	 approach	 is	 effective	 in	 filtering	out	 certain	 agents	 of	 the	 high-risk	 variant,	 it	leaves	gaps	where	 the	cell-genetic	 interaction	 is	not	 considered.	 For	 example,	 transformation	 of	select	 genes	 from	 ebola	 virus	 into	 low	 risk	organisms	 may	 not	 warrant	 high-risk	classification	 even	 though	 the	 gene	 of	 ebola	origin	would	be	considered	high	risk.	Or	perhaps	interaction	 between	 a	 low	 risk	 gene	 and	 a	 low	risk	 organism,	 for	 example	 the	 introduction	 of	antibiotic	resistance	genes	in	certain	gut	bacteria	for	 probiotic	 applications,	 could	warrant	 higher	risk	classifications	as	a	therapeutic.		
Adaptive	Drug	Assessment	Process	The	 United	 States	 Environmental	Protection	 Agency	 has	 classified	 intergeneric	microorganisms	 as	 being	 distinct	 from	 other	microorganisms	 and	 has	 created	 regulations	specific	 to	 them	 [15].	 Canada	 should	 adopt	 a	similar	 policy	 regarding	 modified	microorganisms	 that	 account	 for	 their	 unique	properties,	 namely	 the	 likelihood	 of	 emergent	properties.	 Emergent	 properties	 refer	 to	 the	possibility	 of	 unpredictable	 phenotypes	 arising	due	to	the	 interactions	of	exogenous	genes	with	endogenous	genes,	other	cellular	components,	or	other	 cells.	 Because	 of	 the	 unpredictability	 of	these	emergent	properties,	it	will	be	necessary	to	improve	 current	 risk	 assessment	 procedures	 as	well	 as	 introduce	 long	 term	 plans	 for	 effective	monitoring	 of	 manipulated	 cells	 once	 they	 are	released	to	the	market	[16].	The	 translation	 of	 research	 for	biotherapeutics	 (particularly	 from	 research	 in	model	organisms	to	clinical	research	in	humans)	is	not	as	linear	as	drugs	currently	on	the	market,	due	 to	 these	 emergent	 properties	 [11].	 Thus	strategies	 to	 mitigate	 adverse	 effects	 during	translational	 research	 is	 compulsory.	Consequently,	 the	 research	 ethics	 board	 will	need	 to	 take	 extra	 precaution	 when	 assessing	present	 research	 for	 clinical	 studies	 involving	biotherapeutics,	 as	 well	 as	 set	 up	 frequent	
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monitoring	of	adverse	effects	while	clinical	trials	are	conducted.	This	may	require	the	government	to	 impose	 additional	measures	 in	 authorization	of	such	translational	research.		
Standard	Indicators	Although	there	 is	no	single	standard	that	can	 reveal	 the	 entire	 complexity	 of	 whether	 a	biotherapeutic	will	have	undesired	side	effects,	a	number	 of	 design	 specifications	 of	 a	biotherapeutic	 technology	 should	be	considered	when	 assessing	 the	 safety	 of	 the	 technology.	These	 design	 specifications	 include,	 but	 are	 not	limited	to:	
• the	 presence	 of	 kill-switch	 technology	(genes	 incorporated	 such	 that	 certain	environmental	exposure	causes	the	cell	to	commit	to	apoptosis);	
• the	presence	of	auxotrophy	(knocking	out	genes	for	essential	nutrients	of	the	cell	so	that	 it	 cannot	 survive	 without	 an	abundance	 of	 said	 nutrient	 in	 its	immediate	surroundings);	
• reporting	 on	 reproductive	 capabilities	 of	cell	product;	
• whether	 the	 cell	 type	 is	 likely	 to	 retain	integrated	 genes	 for	 an	 extended	 period	of	 time	 (linked	 to	 the	 insertion	 site	 of	gene,	e.g.	plasmid	vs.	chromosome)	
• promoter	 strength	 (how	 likely	 gene	 is	 to	be	 transcribed	 and	 translated	 into	product,	as	it	relates	to	dosage);	
• reporting	 on	 therapeutic	 cells’	localization	and	migration	abilities;	
• cell	 type	 and	 origin;	 (with	 reference	 to	existing	cell-therapy	regulations)	
• gene	type	and	origin,	and;	(with	reference	to	 existing	 select	 agent	 compliance	regulations)	
• the	 differentiation	 of	 in	 vivo	 vs.	 ex	 vivo	transformations.	Users	 should	 be	 aware	 that	 any	 one	 of	these	points	would	not	be	sufficient	to	assess	the	safety	 of	 a	 biotherapeutic	 product;	 instead,	reference	 to	 multiple	 standardized	 indicators	may	be	required.	Benefit-risk	analysis	should	be	conducted	 with	 reference	 to	 standardized	
indicators	on	a	case-by-case	basis.	Standardized	indicators	 could	 offer	 a	 fast	 way	 to	 review	incoming	 biotherapeutic	 proposals,	 although	 it	will	 need	 to	 work	 in	 conjunction	 with	 current	assessments	 to	 inform	 decision	 regarding	 drug	approvals.		
Improving	Pharmacovigilance	
Practices	To	 best	 implement	 biotherapeutic	technologies	for	use	in	the	future,	it	is	important	for	 pharmacovigilance	 practices	 to	 be	 up	 to	 the	same	 standards	 as	 the	 drug	 approval	 process	[17,	 18].	 This	 is	 especially	 important	 for	biotherapeutics	 due	 to	 the	 proliferative	 and	adaptive	 properties	 of	 cells,	 which	 makes	 even	the	smallest	contamination	issue	potentially	far-reaching	and	detrimental	[19].	Although	Canada	currently	 has	 mandates	 for	 pharmacovigilance	under	 section	C.05.010(f)	 of	 the	 Food	 and	Drug	Regulations,	 numerous	 systematic	 reviews	have	cited	 the	 pitfalls	 of	 Canada’s	 current	pharmacovigilance	 system,	 particularly	 the	issues	of	under-reporting	of	adverse	drug	events	and	 long	 processing	 times	 [9].	 A	 qualitative	study	 of	 Canadian	 pharmacovigilance	 identified	that	 only	 3%	 of	 all	 adverse	 reactions	 get	reported,	 and	 the	 overall	 reviewing	 times	 take	months	 after	 the	 actual	 occurrence	 of	 said	adverse	 drug	 events	 [9,	 10].	 Under	 these	circumstances,	even	modest	modifications	could	yield	 significant	 results.	 The	 proposed	modifications	to	consider	include:	
• an	 increase	 in	 reporting	 frequency	 by	encouraging	 participation	 of	 both	community	and	institutional	pharmacists,	physicians,	 and	 affiliated	 institutions	 as	well	 as	 giving	 individual	 patients	 the	option	 of	 reporting	 of	 adverse	 drug	events;	
• imposing	 accountability	 measures	 for	companies	 and	 professionals	 that	 do	 not	report	adverse	events	in	compliance	with	good	 pharmacovigilance	 practices,	including	 the	 mishandling	 or	 intentional	release	of	products;	
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• an	 intuitive	online	reporting	system	with	categorical	data	that	is	easily	compiled	for	reviewing	purposes,	and;	
• a	 coordinated	 effort	 between	epidemiologic	 personnel	 in	 the	 Public	Health	 Agency	 of	 Canada	 and	 the	pharmacovigilance	 review	board	 to	 react	quickly	to	adverse	events	or	leaks.	Optimal	use	should	be	made	of	 the	above	strategies,	 but	 there	 are	 certain	 limitations	 to	each	 and	 alternative	 or	 fastidious	 strategies	might	 be	 necessary.	 These	 modifications	 are	meant	 to	 be	 restricted	 to	 any	 future	biotherapeutic	 products,	 as	 implementation	 for	all	drugs	could	be	costly	and	cumbersome.		
Building	Local	Expertise	and	Know-
How	 Historically,	 the	 release	 of	 any	 novel	technology	has	faced	opposition	from	the	public	and	lobby	groups	due	to	a	lack	of	understanding.	Often,	 individuals	 who	 might	 benefit	 from	 the	technology	 miss	 opportunities	 due	 to	misconceptions	 and	 stigmas.	 For	 these	 reasons,	training	 and	 public	 education	 are	 particularly	vital	 to	 avoid	 misuse	 and	 to	 obtain	 maximum	benefit.	 Training	 with	 these	 new	 technologies	should	 be	 extended	 to	 relevant	 ministries,	authorized	health	professionals,	and	community	advocates.	 In	 terms	 of	 content,	 the	 training	should	 involve	 both	 theoretical	 science	 and	physical	 handling	 skills	 of	 each	 biotherapeutic.	Individuals	 should	 know	 its	 basic	 operation	 as	well	as	troubleshooting	and	emergency	reaction	protocols	 upon	 training	 completion.	 Public	education	 concerning	 the	 science	 involved	 in	genetically	engineered	devices	is	equally	vital	to	prevent	 stigmatization.	 This	 involves	 an	integrated	effort	between	education	boards	and	health	ministries.	The	advantages	of	professional	training	and	public	education	include	the	access	of	biotherapeutics	by	individuals	who	need	them	to	 maximize	 societal	 benefit,	 as	 well	 as	minimizing	incidence	of	misuse.		
International	Harmonization	Biotherapeutics	 also	 offer	 many	
advantages	in	foreign	settings,	 including	but	not	limited	to	ease	of	use,	minimal	maintenance,	and	self-reproducibility	 [1].	 With	 increasing	international	 travel	 and	 migration,	 there	 is	 a	resulting	 increasing	 demand	 for	 the	pharmaceutical	 industry	 to	 be	 regulated	 on	 the	global	 scale,	 as	 the	 development	 in	 the	biotechnological	 industry	 is	 occurring	 around	the	 globe.	 Local,	 national,	 and	 international	efforts	 are	 needed	 to	 gain	 more	 insight	 on	 the	potential	ways	 to	 increase	safety	and	efficacy	of	biotherapeutics;	 this	 may	 include	 specific	international	guidelines	established	 through	 the	International	Conference	of	Harmonization	(ICH)	[20].	 	
Building	Innovative	Research	
Networks	Ensuring	 the	 safety	 and	 efficacy	 of	biotherapeutics	 should	 involve	 coordinated	efforts	 across	 many	 sectors	 –	 the	 health,	education,	labor,	civil	service	and	private	sectors	–	and	the	Canadian	regulatory	system,	academic	institutions	 and	 other	 stakeholders.	 It	 is	therefore	 important	 to	 distinguish	 and	strengthen	 mechanisms	 that	 bring	 together	producers,	 regulators,	 and	 end	 users	 of	biotherapeutic	products.	This	could	be	achieved	by	 increasing	 awareness	 and	 funding	 of	biotherapeutics	 in	 government.	 Potential	benefits	 include	 increasing	 drug	 research	innovativeness,	 consolidation	 between	 the	 lab	bench	and	the	public,	and	higher	ability	to	better	address	 health	 demands	 while	 still	 being	 strict	on	issues	such	as	bioterrorism.	The	Cartagena	Protocol	 is	a	 step	 that	 the	international	community	has	taken	to	get	closer	to	 increasing	 cooperation	 between	 sectors	 by	governing	the	movement	of	biotherapeutics	from	one	 country	 to	 another,	 and	 it	 has	 valid	 points	regarding	 the	 development	 of	 biotherapeutics	[16].	 In	 practice,	 such	 a	 network	 does	 not	 yet	exist	 on	 the	 international	 scale.	 Canada,	 as	 an	international	 leader	 of	 progressive	 health	policies,	 should	 develop	 strategies	 toward	 this	end.		
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Conclusion	The	 advancing	 industry	 of	biotherapeutics	 is	 supplying	 society	with	 novel,	promising	 drugs	 which	 may	 pose	 risks	 if	 their	production,	 distribution,	 and	marketing	 are	 not	governed	by	 legislation.	As	 there	are	no	specific	regulations	 in	 Canada	 governing	 manipulated	cell-based	therapeutics,	the	introduction	of	these	laws	and	regulations	in	Canada	will	be	beneficial	in	 authorising	 the	 safe	 research	 and	 use	 of	biotherapeutics.	Strategies	attempting	 to	address	 this	gap	in	 therapeutic	 regulation	 should	 include	 an	adaptive	drug	licensing	process	which	makes	use	of	 existing	 standard	 indicators	 commonly	 used	by	researchers,	a	cooperative	pharmacovigilance	strategy	for	post-market	monitoring,	as	well	as	a	local	 and	 international	 research	 network	which	increases	 access	 to	 biotherapeutics	 for	 those	who	 need	 it	 while	 preventing	 misuse	 and	bioterrorism	acts.	
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